Trimming Undruggable Cancer Targets, and more

Cancer Stories From The Scientist

View in browser September 13, 2023 Advertisement   Trimming Undruggable Cancer Targets By Deanna MacNeil, PhD Researchers took aim at mucins, glycoproteins that protect cancer cells from drugs and the immune response, and engineered a revolutionary targeted tool for oncology and beyond.     Case Study: Building Better Drugs for Cancer and Beyond By Synthego In cases where conventional drugs are insufficient, PROTACs can inactivate targets by bringing them into contact with protein degraders. In this case study from Synthego, learn how a researcher used a CRISPR knockout cell pool to validate a protein degrader's mechanism of action.   Advertisement   A Long and Unhealthy Life? By Aparna Nathan, PhD Glycogen and N-linked glycans accumulate in fibrotic regions of the lung and may be important for therapy development.     Article: Assessing Drug Cytotoxicity through Artificial Intelligence By Sartorius Using a novel software module, researchers quantify cell viability from microscopy images without needing fluorescent labels. Learn more in this article from Sartorius.   The Scientist's Creative Services Team inbox is always open, so if you have questions or comments, we'd love to hear from you. Send Us Your Feedback »   Never miss an email from The Scientist. Click here to add The Scientist to your safe-sender list. The Scientist, 1000 N West Street, Suite 1200,  Wilmington, Delaware, United States, 19801   Toll-Free: (888) 781-0328 | Phone: (705) 528-6888 Email: privacy@the-scientist.com www.the-scientist.com You received this email because you are subscribed to The Scientist Special Offers and Promotions from The Scientist. Click to Unsubscribe | View Privacy Policy Stop receiving email from The Scientist